MBIO / FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focu more_horizontal

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in p more_horizontal

The mean of analysts' price targets for Mustang Bio, Inc. (MBIO) points to a 711.6% upside in the stock. While this highly sought-after metric has not more_horizontal

Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that more_horizontal

WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focu more_horizontal

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru more_horizontal

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru more_horizontal

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru more_horizontal